Compare LTC Properties Inc (LTC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs TG Therapeutics Inc — how do they compare? LTC Properties Inc trades at $38.12 (market cap $2.05B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 3.7× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.98% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LTC | TGTX | |
|---|---|---|
Market Cap | $2.05B | $7.64B |
Sector | Real Estate | Health |
52-Week High | $42.81 | $59.06 |
52-Week Low | $33.98 | $26.94 |
Enterprise Value | $2.79B | $7.84B |
Dividend Yield | 5.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties (LTC) trades at $38.69, down 1.85% over 24 hours, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported Q2 2026 earnings that beat expectations, with EPS of $0.56 versus $0.48 expected, and continues aggressive SHOP portfolio expansion, with recent acquisitions totaling over $285 million year-to-date. Revenue grew to $262.85 million in 2025, and net income margin remains strong at 38.93%, though recent quarters show mixed earnings performance.
LTC presents a mixed outlook; strong fundamentals and dividend yield near 5.9% appeal to income investors, but bearish technicals and elevated debt levels pose risks. Analyst consensus is cautious with 59% hold ratings, reflecting concerns over execution amid rapid portfolio growth. Key catalysts include SHOP acquisition success and demographic tailwinds, while risks involve interest rate sensitivity and integration challenges.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
